In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
In this article, we're going to dive deep into why the DEA is dragging its…
As the movement for marijuana legalization gains momentum across the United States, a significant barrier…
Conventional treatments prescribed to treat autoimmune conditions are focused on taming inflammation; these usually include…
Discover deals like daily $10 eighths for the holiday weekend and beyond at Giving Tree…
Verilife Non-Medical Cannabis is now available in Ohio. Open to customers 21+ with a valid…
At Verilife, there's always a stocked selection of top products & new favorites. Find the…